{"id":"NCT03633617","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)","officialTitle":"A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-24","primaryCompletion":"2021-09-09","completion":"2022-06-07","firstPosted":"2018-08-16","resultsPosted":"2022-12-28","lastUpdate":"2023-06-28"},"enrollment":321,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Esophagitis"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["DUPIXENT","REGN668","SAR231893"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Part A: Dupilumab or Placebo","type":"EXPERIMENTAL"},{"label":"Part B: Dupilumab or Placebo","type":"EXPERIMENTAL"},{"label":"Part C: Dupilumab","type":"EXPERIMENTAL"}],"summary":"The primary objectives of the study by study part are:\n\nPart A:\n\nTo determine the treatment effect of dupilumab compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures and to inform/confirm the final sample size determination for Part B.\n\nPart B:\n\nTo demonstrate the efficacy of dupilumab treatment compared with placebo in adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures.\n\nPart C:\n\nTo assess the safety and efficacy of dupilumab treatment in adult and adolescent patients with EoE after up to 52 weeks of treatment as assessed by histological and clinical measures.\n\nThe secondary objectives of the study are:\n\n* To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 52 weeks in adult and adolescent patients with EoE\n* To explore the relationship between dupilumab concentration and responses in adult and adolescent patients with EoE, using descriptive analyses\n* To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation\n* To demonstrate the efficacy of dupilumab treatment compared to placebo after 24 weeks and 52 weeks of treatment in adult and adolescent patients with EoE who have previously received swallowed topical corticosteroids","primaryOutcome":{"measure":"Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of â‰¤6 Eosinophils Per High-power Field (Eos/Hpf) in All Three Regions at Week 24","timeFrame":"At week 24","effectByArm":[{"arm":"Part A: Placebo","deltaMin":5.1,"sd":null},{"arm":"Part A: Dupilumab 300 mg SC QW","deltaMin":59.5,"sd":null},{"arm":"Part B: Placebo","deltaMin":6.3,"sd":null},{"arm":"Part B: Dupilumab 300 mg SC Q2W","deltaMin":60.5,"sd":null},{"arm":"Part B: Dupilumab 300 mg SC QW","deltaMin":58.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"},{"comp":"OG002 vs OG004","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":95,"countries":["United States","Australia","Belgium","Canada","France","Germany","Italy","Netherlands","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["39909733","38940435","38050037","38010430","37660704","36546624"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":39},"commonTop":["Injection site reaction","Injection site erythema","Injection site pain","Headache","COVID-19"]}}